Protective effects of Astragalus saponin I on early stage of diabetic nephropathy in rats

Journal of Pharmacological Sciences

Volumn 95, Issue 2, 2004, Pages 256-266

  Yin, Xiaoxing ^a   Zhang, Yindi ^a   Wu, Haiwei ^a   Zhu, Xiang ^a   Zheng, Xiaogang ^b   Jiang, Shaojun ^b   Zhuo, Haitong ^a   Shen, Jianping ^a   Li, Limin ^a   Qiu, Jun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

Astragalus membranaceus; Astragalus saponin I; Diabetic nephropathy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; ALDEHYDE REDUCTASE; ASTRAGALUS MEMBRANACEUS EXTRACT; ASTRAGALUS SAPONIN 1; EPALRESTAT; GLUCOSE; SAPONIN; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTRAGALUS MEMBRANACEUS; CELL PROTECTION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ELECTRON MICROSCOPY; ENZYME ACTIVITY; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE BLOOD LEVEL; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; MALE; MESANGIUM; MICROALBUMINURIA; NONHUMAN; OXIDATIVE STRESS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; THICKNESS;

ASTRAGALUS;

EID: 3142586947     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.FP0030597     Document Type: Article

References (46)

1. Cooper ME, Gilbert RE, Epstein M. Pathophysiology of diabetic nephropathy. Metabolism. 1998;47 Suppl 1:3-6.
2. Cruz M, Ruiz-Torres P, Alcami J, et al. Hydrogen peroxide increses extracellular matrix mRNA through TGF-β in human mesangial cells. Kidney Int. 2001;59:87-95.
3. Oates PJ, Mylari BL. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin Invest Drugs. 1999;8:2095-2119.
4. Ishii H, Tada H, Isogai S. An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-beta and protein kinase C activity in cultured human mesangial cells. Diabetologia. 1998;41:362-364.
5. Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney. 2001;38 Suppl 1:S100-S106.
6. Kelly DJ, Cox AJ, Tolcos M, Cooper ME, Wilkinson-Berka JL, Gilbert RE. Attenuation of tubular apoptosis by blockade of the rennin-angiotensin system in diabetic Ren-2 rats. Kidney Int. 2002;61:31-39.
7. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia. 2001;44:1957-1972.
8. Toda S, Yase Y, Shirataki Y. Inhibitory effects of astragali radix, crude drug in Oriental medicines on lipid peroxidation and protein oxidative modification of mouse brain homogenate by copper. Phytother Res. 2000;14:294-296.
9. Verotta L, Guerrini M, El-Sebakhy NA, et al. Cycloartane and oleanane saponins from Egyptian astragalus app. as modulators of lymphocyte proliferation. Planta Med. 2002;68:986-994.
10. You LF, Zhang YD. The effect of Astragalous saponins on MΦ phagocytic function and long-term culture of murine peritoneal macrophage. J Nanjing Med Coll. 1993;7:39-43.
11. Zhang YD, Shen JP, Zhu SH, Huang DK, Ding Y, Zhanf XL. Effect of Astragalus (ASI, SK) on experimental liver injury. Acta Pharm Sin. 1992;27:401-406.
12. Wang Q. Intropic action of Astragalus membrananeus Bge. saponin and its possible mechanism. Chin J Chin Materia Med. 1992;17:557-559.
13. Zhang WJ, Wojta J, Binder BR. Regulation of fibrinolytic potential of cultured human umbilical vein endothelial cell: Astragaloside IV downregulates plasminogen activator inhibitor-I and upregulates tissue-type plasminogen activator expression. J Vasc Res. 1997;34:73-80.
14. Zhao Th. Positive modulating action of Shengmaisan with Astragalus membranaceus on anti-tumor activity of LAK cell. Chin J Integr Tradit West Med. 1993;13:471-472.
15. .OH. J Chin Material Med. 1999;22:303-306.
16. Yuan CH, Liu YF, Cheng Y. Experimental study on effect of Astragalus extractum on canine isolated kidney during hypothermia perfusion and preservation. Chin J Integr Tradit West Med. 2003;23:291-293.
17. Ni ZH, Zhang QY, Qian JQ, Wang LM, Wang JH. Effect of Astrgalin on matrix secretion and β1 integrin mRNA expression in human mesangial cells. Chin J Nephrol. 2000;16:303-307.
18. Jiang QL, Li YJ, Xin H, Jiang JW, Lu XX, Zhu JX. Effects of ASI on insulin and C-peptide. Heilongjiang Med Pharm. 1999;22:14.
19. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci. 1993;84:407-412.
20. Yu L, Qiu HX, Chen WY, et al. The relationship between advanced glycosylation end products and the extracellular matrix of aorta in diabetic rats. Chin J Arterioscler. 1999;7:311-314.
21. Blownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes. 1985;34:938-943.
22. Srivasitava SK, Ansari NH, Hair GA, et al. Aldose and aldehyde reductase in human tissue. Biochim Biophys Acta. 1984;800: 220-225.
23. Shankland SJ, Scholey JW. Expression of TGF-β1 during diabetic renal hypertrophy. Kidney Int. 1994;46:430-438.
24. Zheng X, Luo J, Yang WY, et al. Role of nitric oide on diabetic nephropathy. Chin J Nephrol. 1999;15:91-95.
25. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356-360.
26. Liu ZQ, Li QZ, Qin GJ. Effect of Astragalus injection on platelet function and plasma endothelin in patients with early stage diabetic nephropathy. Chin J Integr Tradit West Med. 2001;21:274-276.
27. Ma HX, Li DM. Effects of Astragalus saponin on hormone in diabetic rat serum. Studies Trace Element Health. 2003;20:5-6.
28. ε-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest. 1997;99 457-468.
29. Ihm SH, Yoo HJ, Park SW, Ihm J. Effect of aminiguanidine on lipid peroxidation in streptozotocin-induced diabetic rats. Metabolism. 1999;48:1141-1145.
30. Min C, Kang E, Yu S-K, Shinn S-H, Kim Y-S. Advanced glycation end products induce apoptosis and procoagulant activity in cultured human umbilical vein endothelial cells. Diab Res Clin Pract. 1999;46:197-202.
31. Koya D, Hayashi K, Kitada M, Kashiwagi A, Kikkawa R, Haneda M. Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J Am Soc Nephrol. 2003;14 8 Suppl 3:S250-S253.
32. Ueno Y, Horio F, Uchida K, et al. Increase in oxidative stress in kidneys of diabetic Akita mice. Biosci Biotechnol Biochem. 2002;66:869-872.
33. Catherwood MA, Powell LA, Anderson P, McMaster D, Sharpe PC, Trimble ER. Glucose-induced oxidative stress in mesangial cells. Kidney Int. 2002;61:599-608.
34. Feng P, Wang XJ. Antioxidant activity of Qizhu Tang. Acta Pharmacol Sin. 2000;21:1141-1144.
35. Yan Y, Chen MZ. Inhibitory effect of total extract of Astragalus on hepatocyte apoptosis. Chin J Pharmacol Toxicol. 2001;15: 287-292.
36. Lei H, Wang B, Li WP, Yang Y, Zhou AW, Chen MZ. Antioxidative effect of total extract of astragalus (TEA) on aging mice. Chin J Clin Pharmacol Ther. 2000;5:298-301.
37. Tajiri Y, Grill VE. Interactions between vitamin E and glucose on B-cell functions in the rat: an in vivo and in vitro study. Pancreas. 1999;18:274-281.
38. Ihara Y, Yamada Y, Toyokuni S, et al. Antioxidant alphatocopherol ameliorates glycemic control of GK rats, a model of type 2 diabetes. FEBS Lett. 2000;473:24-26.
39. Kaneto H, Kajimoto Y, Miyagawa J, et al. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity. Diabetes. 1999;48:2398-2406.
40. Oates PJ, Mylari BL. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin Invest Drugs. 1999;8:2095-2119.
41. Greene DA, Lattimer SA, Sima AAF. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med. 1987;316:599-606.
42. Gruden G, Thomas S, Burt D, et al. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J Am Soc Nephrol. 1999;10:730-737.
43. Herman WH, Emancipator SN, Rhoten RLP, Simonson MS. Vascular and glomerular expression of endothelin-1 in normal human kidney. Am J Physiol Renal Physiol. 1998;44:F8-F17.
44. Jandeleit-Dahm K, Cao ZM, Cox AJ, Kelly DJ, Gilbert RE, Cooper ME. Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int. 1999;56:S31-S36.
45. Montero A, Munger KA, Khan RZ, et al. F-2-isoprostanes mediate high glucose-induced TGF-beta synthesis and glomerular proteinuria in experimental type I diabetes. Kidney Int. 2000;58:1963-1972.
46. Xu YJ, Zhang QY, Lu M, Zhao HF, Chen SS. Effect of Astragulus membranaceus on expression of TGF-β in renal cortex of diabetic rats. Chin J Endocrinol Metab. 1998;14:312-314.